[go: up one dir, main page]

MA33157B1 - Acétamides à substitution n-(hétéro)aryl, 2-(hétéro)aryle pour une utilisation en tant que modulateurs de la voie de signalisation wnt - Google Patents

Acétamides à substitution n-(hétéro)aryl, 2-(hétéro)aryle pour une utilisation en tant que modulateurs de la voie de signalisation wnt

Info

Publication number
MA33157B1
MA33157B1 MA34217A MA34217A MA33157B1 MA 33157 B1 MA33157 B1 MA 33157B1 MA 34217 A MA34217 A MA 34217A MA 34217 A MA34217 A MA 34217A MA 33157 B1 MA33157 B1 MA 33157B1
Authority
MA
Morocco
Prior art keywords
hetero
aryl
signaling pathway
modulators
wnt signaling
Prior art date
Application number
MA34217A
Other languages
Arabic (ar)
English (en)
Inventor
Dai Cheng
Guobao Zhang
Dong Han
Wenqi Gao
Shifeng Pan
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42112245&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33157(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Irm Llc filed Critical Irm Llc
Publication of MA33157B1 publication Critical patent/MA33157B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Steroid Compounds (AREA)

Abstract

LA PRÉSENTE INVENTION PORTE SUR DES COMPOSÉS DE FORMULES 1 ET 2 ET SUR DES PROCÉDÉS DE MODULATION DE LA VOIE DE SIGNALISATION WNT À L'AIDE DE CES COMPOSÉS, DANS LESQUELS A1, A2, B, Y ET Z REPRÉSENTENT TOUS DES CYCLES.
MA34217A 2009-03-02 2010-03-01 Acétamides à substitution n-(hétéro)aryl, 2-(hétéro)aryle pour une utilisation en tant que modulateurs de la voie de signalisation wnt MA33157B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15659909P 2009-03-02 2009-03-02
US24518709P 2009-09-23 2009-09-23
PCT/US2010/025813 WO2010101849A1 (fr) 2009-03-02 2010-03-01 Acétamides à substitution n-(hétéro)aryl, 2-(hétéro)aryle pour une utilisation en tant que modulateurs de la voie de signalisation wnt

Publications (1)

Publication Number Publication Date
MA33157B1 true MA33157B1 (fr) 2012-03-01

Family

ID=42112245

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34217A MA33157B1 (fr) 2009-03-02 2010-03-01 Acétamides à substitution n-(hétéro)aryl, 2-(hétéro)aryle pour une utilisation en tant que modulateurs de la voie de signalisation wnt

Country Status (40)

Country Link
US (4) US8546396B2 (fr)
EP (2) EP2403832B1 (fr)
JP (2) JP5490153B2 (fr)
KR (1) KR101359873B1 (fr)
CN (2) CN102369187B (fr)
AR (1) AR076067A1 (fr)
AU (1) AU2010221493C1 (fr)
BR (1) BRPI1009235B8 (fr)
CA (1) CA2753552C (fr)
CL (1) CL2011002116A1 (fr)
CO (1) CO6450669A2 (fr)
CR (2) CR20190039A (fr)
CU (1) CU24050B1 (fr)
DK (1) DK2403832T3 (fr)
DO (1) DOP2011000273A (fr)
EA (1) EA021225B1 (fr)
EC (1) ECSP11011359A (fr)
ES (2) ES2543320T3 (fr)
GE (2) GEP20146033B (fr)
HN (1) HN2011002346A (fr)
HR (1) HRP20140156T1 (fr)
IL (1) IL214516A (fr)
JO (1) JO2933B1 (fr)
MA (1) MA33157B1 (fr)
MX (1) MX2011009246A (fr)
MY (1) MY150583A (fr)
NI (1) NI201100165A (fr)
NZ (2) NZ595339A (fr)
PE (1) PE20120650A1 (fr)
PL (1) PL2403832T3 (fr)
PT (1) PT2403832E (fr)
SG (1) SG173467A1 (fr)
SI (1) SI2403832T1 (fr)
SM (1) SMT201400032B (fr)
TN (1) TN2011000378A1 (fr)
TW (2) TW201329070A (fr)
UA (1) UA103918C2 (fr)
UY (2) UY32469A (fr)
WO (1) WO2010101849A1 (fr)
ZA (1) ZA201106750B (fr)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA103918C2 (en) 2009-03-02 2013-12-10 Айерем Элелси N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
CA2756535A1 (fr) 2009-03-23 2010-09-30 Glenmark Pharmaceuticals, S.A. Derives de furopyrimidinedione a titre de modulateurs de trpa1
KR20130016244A (ko) * 2010-03-10 2013-02-14 인게니움 파르마코이티칼스 게엠베하 단백질 키나아제의 억제제
UY33469A (es) * 2010-06-29 2012-01-31 Irm Llc Y Novartis Ag Composiciones y metodos para modular la via de señalizacion de wnt
EP2605652B1 (fr) 2010-08-18 2017-11-08 Samumed, LLC Dicétones et hydroxydicétones utiles en tant qu'activateurs de la voie de signalisation de la caténine
EP2573085A1 (fr) 2011-09-26 2013-03-27 AiCuris GmbH & Co. KG Monohydrate de mesylate acétamide N-[5-(aminosulfonyl)-4méthyl-1,3-thiazol-2-yl]-N-méthyl-2-[4-(2-pyridinyl)phényl] disposant d'une gamme de distribution de taille de particules spécifiques et portée de surface spécifique
EP2573086A1 (fr) * 2011-09-26 2013-03-27 AiCuris GmbH & Co. KG Monohydrate de mesylate acétamide N-[5-(Aminosulfonyl)-4-méthyl-1,3-thiazol-2-yl]-N-méthyl-2-[4-(2-pyridinyl)phényl]
EP3693476B1 (fr) * 2012-02-28 2023-10-18 Novartis AG Sélection de patients atteints d'un cancer pour l'administration d'inhibiteurs de la voie de signalisation de wnt au moyen de l'état mutationnel de rnf43
WO2013138753A1 (fr) 2012-03-16 2013-09-19 Fox Chase Chemical Diversity Center, Inc. Promédicaments de riluzole et leur méthode d'utilisation
US9234176B2 (en) * 2012-11-13 2016-01-12 The Board Of Trustees Of The Leland Stanford Junior University Chemically defined production of cardiomyocytes from pluripotent stem cells
KR101418168B1 (ko) * 2012-11-21 2014-07-09 부경대학교 산학협력단 신규 테트라하이드로피리디놀 유도체 화합물 및 이를 유효성분으로 포함하는 암 예방 또는 치료용 약제학적 조성물
MA38421A1 (fr) 2013-02-22 2017-03-31 Samumed Llc Gamma-dicétones en tant qu'activateurs de la voie de signalisation wnt/?-caténine
CN103113353B (zh) * 2013-03-13 2014-09-10 中国科学院昆明植物研究所 三氮唑类化合物，其药物组合物和其制备方法与应用
TWI582239B (zh) 2013-03-11 2017-05-11 諾華公司 與ｗｎｔ抑制劑相關之標記
US9713612B2 (en) 2013-03-12 2017-07-25 Curegenix, Inc. Compounds for treatment of cancer
GB2513403A (en) * 2013-04-26 2014-10-29 Agency Science Tech & Res WNT pathway modulators
GB201309333D0 (en) 2013-05-23 2013-07-10 Agency Science Tech & Res Purine diones as WNT pathway modulators
US9914740B2 (en) 2013-07-02 2018-03-13 Bristol-Myers Squibb Company Tricyclic pyrido-carboxamide derivatives as rock inhibitors
ES2634628T3 (es) 2013-07-02 2017-09-28 Bristol-Myers Squibb Company Derivados tricíclicos de pirido-carboxamida como inhibidores ROCK
HK1225718A1 (zh) 2013-08-30 2017-09-15 Ambit Biosciences Corporation 联芳基乙酰胺化合物及其使用方法
WO2015048312A1 (fr) 2013-09-26 2015-04-02 Costim Pharmaceuticals Inc. Méthodes de traitement de cancers hématologiques
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
LT3116909T (lt) 2014-03-14 2020-02-10 Novartis Ag Antikūno molekulės prieš lag-3 ir jų panaudojimas
WO2015145388A2 (fr) 2014-03-27 2015-10-01 Novartis Ag Procédés de traitement de cancers colorectaux avec mutations en amont de la voie wnt
WO2015169762A1 (fr) * 2014-05-06 2015-11-12 F. Hoffmann-La Roche Ag Méthode de différenciation de cellules souches pluripotentes en cardiomyocytes
PT3206686T (pt) 2014-08-20 2020-01-06 Samumed Llc Gama-dicetonas para o tratamento e prevenção de rugas e do envelhecimento da pele
US9765299B2 (en) 2014-09-10 2017-09-19 Wisconsin Alumni Research Foundation Chemically defined albumin-free conditions for cardiomyocyte differentiation of human pluripotent stem cells
CA2960824A1 (fr) 2014-09-13 2016-03-17 Novartis Ag Therapies combinees d'inhibiteurs d'alk
ES2922580T3 (es) 2014-10-08 2022-09-16 Redx Pharma Plc Derivados de N-piridinilacetamida como inhibidores de la ruta de señalización WNT
WO2016055786A1 (fr) * 2014-10-08 2016-04-14 Redx Pharma Plc Dérivés de n-pyridyl acétamide utilisés comme inhibiteurs de la voie de signalisation wnt
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
JP6877339B2 (ja) 2014-10-14 2021-05-26 ノバルティス アーゲー Ｐｄ−ｌ１に対する抗体分子およびその使用
WO2016100882A1 (fr) 2014-12-19 2016-06-23 Novartis Ag Polythérapies
US20180044306A1 (en) * 2015-02-20 2018-02-15 Bayer Pharma Aktiengesellschaft 1,3,4-thiadiazol-2-yl-benzamide derivatives as inhibitors of the wnt signalling pathway
JP6692826B2 (ja) 2015-03-10 2020-05-13 アドゥロ バイオテック，インク． 「インターフェロン遺伝子刺激因子」依存性シグナル伝達の活性化のための組成物及び方法
CN104876912B (zh) * 2015-04-08 2017-07-21 苏州云轩医药科技有限公司 Wnt信号通路抑制剂及其应用
JP2018522062A (ja) * 2015-05-26 2018-08-09 キュアジェニックス コーポレーション 腫瘍バイオマーカー及びその使用
CN107613980A (zh) * 2015-05-31 2018-01-19 源生公司 用于免疫疗法的组合组合物
AU2016279474B2 (en) 2015-06-16 2021-09-09 Eisai R&D Management Co., Ltd. Anticancer agent
CA2986999C (fr) 2015-06-23 2023-08-08 Eisai R&D Management Co., Ltd. Cristal de compose de (6s,9as)-n-benzyl-6-[(4-hydroxyphenyl)methyl]- 4,7-dioxo-8-({6-[3-(piperazine-1-yl)azetidine-1-yl]pyridine- 2-yl}methyl)-2-(prop-2-en-1-yl)-octahydro-1h-pyra zino[2,1-c][1,2,4]triazine-1-carboxamide
JO3703B1 (ar) * 2015-07-09 2021-01-31 Bayer Pharma AG مشتقات أوكسوبيريدين مستبدلة
US10624949B1 (en) 2015-07-27 2020-04-21 National Technology & Engineering Solutions Of Sandia, Llc Methods for treating diseases related to the wnt pathway
EP3878465A1 (fr) 2015-07-29 2021-09-15 Novartis AG Polythérapies comprenant des molécules d'anticorps tim-3
WO2017019896A1 (fr) 2015-07-29 2017-02-02 Novartis Ag Traitements combinés comprenant des molécules d'anticorps qui se lient à pd-1
EP3964528A1 (fr) 2015-07-29 2022-03-09 Novartis AG Polythérapies comprenant des molécules d'anticorps dirigées contre lag-3
US11136551B2 (en) 2015-09-01 2021-10-05 Ncardia B.V. In vitro method of differentiating a human pluripotent stem cell population into a cardiomyocyte cell population
CN107759584B (zh) * 2016-08-16 2021-06-01 苏州云轩医药科技有限公司 一种具有Wnt信号通路抑制活性的氨基五元杂环化合物及其应用
LT3370768T (lt) 2015-11-03 2022-05-25 Janssen Biotech, Inc. Antikūnai, specifiškai surišantys pd-1, ir jų panaudojimas
CN106749259B (zh) * 2015-11-19 2019-02-01 华东师范大学 一种环戊基嘧啶并吡咯类化合物的合成方法
JP6630844B2 (ja) * 2015-12-07 2020-01-15 蘇州信諾維医薬科技有限公司Ｓｕｚｈｏｕ Ｓｉｎｏｖｅｎｔ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏ．， Ｌｔｄ． ５員複素環式アミド系ｗｎｔ経路阻害剤
EP4424322A3 (fr) 2015-12-17 2025-04-16 Novartis AG Molécules d'anticorps anti-pd-1 et leurs utilisations
WO2017156350A1 (fr) 2016-03-09 2017-09-14 K-Gen, Inc. Méthodes de traitement du cancer
AR108325A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
RU2019101226A (ru) 2016-06-22 2020-07-22 Новартис Аг Ингибиторы wnt для применения при лечении фиброза
WO2018009466A1 (fr) 2016-07-05 2018-01-11 Aduro Biotech, Inc. Composés dinucléotidiques cycliques d'acide nucléique bloqué et leurs utilisations
CN110072528B (zh) 2017-02-08 2022-04-26 卫材R&D管理有限公司 治疗肿瘤的药物组合物
US11406633B2 (en) 2017-02-14 2022-08-09 Novartis Ag Dosing schedule of a Wnt inhibitor and an anti-PD-1 antibody molecule in combination
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
KR20200013644A (ko) 2017-05-16 2020-02-07 에자이 알앤드디 매니지먼트 가부시키가이샤 간세포 암종의 치료
EP3642240A1 (fr) 2017-06-22 2020-04-29 Novartis AG Molécules d'anticorps dirigées contre cd73 et utilisations correspondantes
CN107441045B (zh) 2017-07-21 2018-10-19 广州源生医药科技有限公司 用于递送Wnt信号通路抑制剂的脂质体制剂及其制备方法
CN108586452A (zh) * 2018-01-12 2018-09-28 重庆市碚圣医药科技股份有限公司 一种帕博西尼中间体的合成方法
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
WO2019157085A2 (fr) * 2018-02-06 2019-08-15 Vanderbilt University Inhibition de la signalisation wnt/bêta-caténine dans le traitement de l'arthrose
AU2018413791B2 (en) * 2018-03-23 2023-05-18 Step Pharma S.A.S. Aminopyrimidine derivatives as CTPS1 inhibitors
TWI869346B (zh) 2018-05-30 2025-01-11 瑞士商諾華公司 Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
WO2020014652A1 (fr) * 2018-07-13 2020-01-16 New York University Macrocycles peptoïdes-peptidiques, compositions pharmaceutiques et leurs procédés d'utilisations
US10961534B2 (en) 2018-07-13 2021-03-30 University of Pittsburgh—of the Commonwealth System of Higher Education Methods of treating porphyria
US12534762B2 (en) 2018-09-28 2026-01-27 Children's Medical Center Corporation Treating atopic dermatitis by targeting the WNT pathway
CN111349093B (zh) * 2018-12-21 2021-07-02 汇瀚医疗科技有限公司 5,6-双环化合物作为wnt信号通路抑制剂及其医学应用
WO2020125759A1 (fr) * 2018-12-21 2020-06-25 汇瀚医疗科技有限公司 Composé en tant qu'inhibiteur de la voie de signalisation wnt et son utilisation médicale
US11369609B2 (en) * 2019-05-02 2022-06-28 Yale University Small molecule Wnt inhibitor as treatment for dyslipidemia
WO2021004467A1 (fr) * 2019-07-08 2021-01-14 南京明德新药研发有限公司 Composé utilisé en tant qu'inhibiteur de porc-épic et son utilisation
CN114502590A (zh) 2019-09-18 2022-05-13 诺华股份有限公司 Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法
JP7461605B2 (ja) * 2020-02-20 2024-04-04 広州白雲山医薬集団股▲フン▼有限公司白雲山制薬総廠 キノリン系化合物
IT202000019897A1 (it) * 2020-08-10 2022-02-10 Olon Spa Procedimento per la preparazione di un intermedio chiave del siponimod
IL301285A (en) 2020-09-10 2023-05-01 Precirix N V A portion of an antibody against FAP
CN112472701B (zh) * 2020-12-04 2021-08-31 复旦大学附属中山医院 Wnt抑制剂Wnt-C59在制备治疗SCN5A突变致扩张型心肌病的药物中的应用
WO2023072263A1 (fr) * 2021-10-29 2023-05-04 南京明德新药研发有限公司 Composé de pyridine-2(1h)-cétone 5-substituée et son utilisation
KR102416464B1 (ko) * 2021-11-24 2022-07-05 중앙대학교 산학협력단 Lgk974를 포함하는 염증성 신장질환 예방 또는 치료용 조성물
WO2023203135A1 (fr) 2022-04-22 2023-10-26 Precirix N.V. Anticorps radiomarqué amélioré
WO2023213801A1 (fr) 2022-05-02 2023-11-09 Precirix N.V. Pré-ciblage
CN116514779B (zh) * 2022-05-06 2025-07-01 长沙晶易医药科技股份有限公司 2,4-二取代-5-氟嘧啶衍生物及其制备方法和应用
WO2024009232A1 (fr) * 2022-07-05 2024-01-11 Aurigene Oncology Limited Dérivés n-(pyridin-2-yl)acétamide substitués en tant qu'inhibiteurs de cdk12/13
CN115784839B (zh) * 2022-11-11 2024-06-21 浙江工业大学 一种4-环己基-3-(三氟甲基)苯甲醇的制备方法
CN118496159B (zh) * 2024-07-18 2024-09-24 广州医科大学附属市八医院 一种化合物在制备具有预防和/或治疗肝纤维化作用的药物中的应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4134467A1 (de) 1991-10-18 1993-04-22 Thomae Gmbh Dr K Heterobiarylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
TW225528B (fr) 1992-04-03 1994-06-21 Ciba Geigy Ag
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
US6602677B1 (en) 1997-09-19 2003-08-05 Promega Corporation Thermostable luciferases and methods of production
TWI241295B (en) 1998-03-02 2005-10-11 Kowa Co Pyridazine derivative and medicine containing the same as effect component
US6114365A (en) * 1999-08-12 2000-09-05 Pharmacia & Upjohn S.P.A. Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents
KR100423899B1 (ko) * 2000-05-10 2004-03-24 주식회사 엘지생명과학 세포 증식 억제제로 유용한 1,1-디옥소이소티아졸리딘을갖는 인다졸
JP2002053566A (ja) * 2000-08-11 2002-02-19 Japan Tobacco Inc チアゾール化合物及びその医薬用途
HU228961B1 (en) 2000-09-18 2013-07-29 Eisai R & D Man Co Triazinones and their use as active ingredients of pharmaceutical compositions
TW201041580A (en) * 2001-09-27 2010-12-01 Alcon Inc Inhibitors of glycogen synthase kinase-3 (GSK-3) for treating glaucoma
US6762185B1 (en) * 2002-03-01 2004-07-13 Choongwae Pharma Corporation Compounds useful for treatment of cancer, compositions containing the same, and methods of their use
FR2847253B1 (fr) 2002-11-19 2007-05-18 Aventis Pharma Sa Nouveaux derives de pyridazinones a titre de medicaments et compositions pharmaceutiques les renfermant
ES2571779T3 (es) * 2002-12-13 2016-05-26 Ym Biosciences Australia Pty Inhibidores de cinasa a base de nicotinamida
CA2509561A1 (fr) 2002-12-18 2004-07-15 Mallinckrodt Inc. Synthese d'acetamides d'heteroaryle
DE10306250A1 (de) 2003-02-14 2004-09-09 Aventis Pharma Deutschland Gmbh Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
TWI372050B (en) * 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
US7652043B2 (en) * 2004-09-29 2010-01-26 The Johns Hopkins University WNT pathway antagonists
GB0507575D0 (en) * 2005-04-14 2005-05-18 Novartis Ag Organic compounds
WO2006116503A2 (fr) 2005-04-26 2006-11-02 Irm Llc Methodes et compositions de modulation de la voie de signalisation wnt
KR20120049397A (ko) 2006-11-03 2012-05-16 노파르티스 아게 단백질 키나제 억제제로서의 화합물 및 조성물
EP1932830A1 (fr) * 2006-12-11 2008-06-18 The Genetics Company, Inc. Sulfamides et leur utilisation en tant que médicament
US20100137394A1 (en) * 2007-04-30 2010-06-03 Grenentech, Inc. Pyrazole inhibitors of wnt signaling
EP2003119A1 (fr) 2007-06-13 2008-12-17 Bayer Schering Pharma Aktiengesellschaft Acétamides substitués en tant que modulateurs du récepteur EP2
MX2010006046A (es) * 2007-12-13 2010-06-23 Amgen Inc Moduladores de gamma secretasa.
US8450363B2 (en) * 2009-02-06 2013-05-28 Elan Pharmaceuticals, Inc. Inhibitors of Jun N-terminal kinase
UA103918C2 (en) * 2009-03-02 2013-12-10 Айерем Элелси N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
UY33469A (es) 2010-06-29 2012-01-31 Irm Llc Y Novartis Ag Composiciones y metodos para modular la via de señalizacion de wnt

Also Published As

Publication number Publication date
EA201101244A1 (ru) 2012-04-30
JP2012519210A (ja) 2012-08-23
ZA201106750B (en) 2013-02-27
AU2010221493B2 (en) 2012-06-07
EA021225B1 (ru) 2015-05-29
JP5490153B2 (ja) 2014-05-14
SG173467A1 (en) 2011-09-29
PE20120650A1 (es) 2012-06-03
ES2445526T3 (es) 2014-03-03
CO6450669A2 (es) 2012-05-31
WO2010101849A1 (fr) 2010-09-10
PL2403832T3 (pl) 2014-04-30
CA2753552A1 (fr) 2010-09-10
BRPI1009235A8 (pt) 2018-01-02
AU2010221493A1 (en) 2011-10-13
HRP20140156T1 (hr) 2014-03-14
DK2403832T3 (da) 2014-01-06
CN102731379B (zh) 2015-05-06
MX2011009246A (es) 2012-09-28
PT2403832E (pt) 2014-01-23
SI2403832T1 (sl) 2014-03-31
AR076067A1 (es) 2011-05-18
CR20110520A (es) 2012-03-26
UY32469A (es) 2010-09-30
TW201329070A (zh) 2013-07-16
ES2543320T3 (es) 2015-08-18
BRPI1009235B1 (pt) 2020-07-14
NZ603137A (en) 2013-02-22
NI201100165A (es) 2012-02-02
CU24050B1 (es) 2014-12-26
UY39128A (es) 2021-04-30
GEP20146082B (en) 2014-04-25
SMT201400032B (it) 2014-07-07
US20180000832A1 (en) 2018-01-04
CU20110165A7 (es) 2012-02-15
NZ595339A (en) 2012-11-30
BRPI1009235B8 (pt) 2021-05-25
KR20110122870A (ko) 2011-11-11
US9238646B2 (en) 2016-01-19
DOP2011000273A (es) 2012-01-31
US20160082014A1 (en) 2016-03-24
GEP20146033B (en) 2014-02-10
MY150583A (en) 2014-01-30
CN102369187A (zh) 2012-03-07
HK1160464A1 (en) 2012-08-17
JO2933B1 (en) 2015-09-15
JP2014129381A (ja) 2014-07-10
TWI429644B (zh) 2014-03-11
CN102369187B (zh) 2014-06-04
CA2753552C (fr) 2014-04-29
EP2403832A1 (fr) 2012-01-11
BRPI1009235A (pt) 2017-08-22
EP2623493A1 (fr) 2013-08-07
KR101359873B1 (ko) 2014-02-06
IL214516A0 (en) 2011-09-27
US20110237573A1 (en) 2011-09-29
IL214516A (en) 2016-10-31
HN2011002346A (es) 2015-03-23
CR20190039A (es) 2019-04-02
EP2403832B1 (fr) 2013-11-20
EP2623493B1 (fr) 2015-04-22
ECSP11011359A (es) 2011-11-30
CL2011002116A1 (es) 2012-01-27
US8546396B2 (en) 2013-10-01
AU2010221493C1 (en) 2013-11-07
TN2011000378A1 (en) 2013-03-27
US10251893B2 (en) 2019-04-09
UA103918C2 (en) 2013-12-10
TW201043622A (en) 2010-12-16
US20130310375A1 (en) 2013-11-21
CN102731379A (zh) 2012-10-17

Similar Documents

Publication Publication Date Title
MA33157B1 (fr) Acétamides à substitution n-(hétéro)aryl, 2-(hétéro)aryle pour une utilisation en tant que modulateurs de la voie de signalisation wnt
MA34388B1 (fr) Compositions et procédés pour moduler la voie de signalisation wnt
EP2283435A4 (fr) Initialisation de diffusion pour des réseaux d'homologue à homologue
MA55046A (fr) Utilisation de dérivés d'indole n-substitués comme modulateurs des récepteurs des pge2
EA201170276A1 (ru) Модуляторы рецептора tgr5 и способы их применения
MX2009008921A (es) Derivados de tiazole en la forma de moduladores de receptores acoplados por proteina g.
EP2067279A4 (fr) Signalisation descendante de configuration d'émetteur pour une estimation cqi
EP2167604A4 (fr) Utilisation d'émulsions époxydiques directes pour stabilisation de puits
EP2408936A4 (fr) Utilisation d'endonucléases thermostables pour générer des molécules rapporteuses
MA53861B1 (fr) Modulateurs de promédicaments de la voie de réponse intégrée au stress
DK2257309T3 (da) Rgd-(bakterie)chlorophyl-konjugater til anvendelse ved diagnose af tumorer, der omfatter nekrotiske domæner
EP2167605A4 (fr) Utilisation d'émulsions époxydiques inverses pour stabilisation de puits
MA35926B1 (fr) Pyrrolidine-2-carboxamides substitués
EP2376641A4 (fr) Procédés de modulation du sexe d'espèces aviaires
EP2531225A4 (fr) Procédés d'utilisation de composés inorganiques hydrosolubles pour implants
EP2436205A4 (fr) Attribution de spectre pour réseaux sur des espaces blancs et d'autres parties du spectre
PE20080830A1 (es) Compuestos derivados de sulfonilo que modulan el receptor cb2
FR2935611B1 (fr) Utilisation d'agents anti-connexines pour moduler l'effet therapeutique de molecules psychotropes
HN2009001436A (es) Nuevo procedimiento de sintesis de la agometatina
EP3768701C0 (fr) Molécules d'agonistes de la signalisation wnt
EP3927869A4 (fr) Méthodes, compositions et dispositifs pour la synthèse à l'état solide de polymères expansibles à utiliser dans le séquençage de molécules individuelles
MA44994A (fr) Composés de modulation des récepteurs adrénergiques et leurs procédés d'utilisation
HN2011000745A (es) Sales de n-[6-cis-2,6-dimetil-morfolin-4-il)-piridin-3-il]-2-metil-4´-(triflouro-metoxi)-[1,1´-bifenil]-3-carboxamida
EP3849564A4 (fr) Composés et méthodes pour moduler l'expression de cln3
MA32834B1 (fr) 3-aminocyclopentanecarboxamides servant de modulateurs de recepteurs de chimiokines